NASDAQ$OLMA
Olema Pharmaceuticals Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Olema Oncology's financial results for Q4 2022 were reported, and a strategic update was provided.
Olema Oncology reported a net loss of $26.2 million for the fourth quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $204.4 million as of December 31, 2022, which is expected to fund operations into 2025. The company is focusing on the late-stage clinical development of OP-1250.
- Significant progress was made in advancing the lead program, OP-1250, with over 170 patients treated to date.
- The first pivotal Phase 3 monotherapy clinical trial of OP-1250 in second- and third-line metastatic breast cancer is set to begin in the second half of 2023.
- A corporate restructuring and portfolio prioritization occurred to focus on the late-stage clinical development of OP-1250.
- Cash, cash equivalents, and marketable securities totaled $204.4 million as of December 31, 2022, expected to fund operations into 2025.
Headline financials
Revenue & EPS history
Olema · Revenue · Quarterly
$0
Forward guidance
Olema Oncology anticipates initiating a pivotal Phase 3 monotherapy clinical trial in the second- and third-line setting of ER+/HER2- advanced or metastatic breast cancer in the second half of 2023. The company also plans to present clinical study results for Phase 2 combination with CDK4/6 inhibitor (palbociclib), Phase 2 monotherapy, and Phase 1b combination with CDK4/6 inhibitor (ribociclib) in the coming quarters.
Tailwinds
- Initiate a pivotal Phase 3 monotherapy clinical trial in the second- and third-line setting of ER+/HER2- advanced or metastatic breast cancer in the second half of 2023.
- Present Phase 2 combination with CDK4/6 inhibitor (palbociclib) clinical study results in the second quarter of 2023.
- Present Phase 2 monotherapy clinical study results in the second half of 2023.
- Present Phase 1b combination with CDK4/6 inhibitor (ribociclib) clinical study results in the second half of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
-0.1%
Avg return
Earnings day
-2.4%
Avg return
5 days after
+7.5%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+17.0%
Q4 2021
Best reaction
-28.5%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.2% | -7.7% | -29.4% | |
| Q3 2025 | +4.1% | +0.6% | +267.4% | |
| Q2 2025 | +16.0% | +20.6% | +75.1% | |
| Q1 2025 | +2.1% | +9.6% | -11.0% | |
| Q4 2024 | -8.5% | +4.3% | +6.8% | |
| Q3 2024 | -9.7% | -27.9% | -47.2% | |
| Q1 2024 | -12.5% | -18.0% | +16.8% | |
| Q4 2023 | -6.6% | -11.2% | -15.8% | |
| Q3 2023 | -7.6% | -7.4% | -29.2% | |
| Q2 2023 | +15.3% | +14.0% | +24.7% | |
| Q1 2023 | +1.1% | +6.1% | -0.3% | |
| Q4 2022 | +0.0% | +0.3% | -15.4% | |
| Q3 2022 | -7.2% | +5.6% | -22.5% | |
| Q2 2022 | -28.5% | -29.4% | -23.1% | |
| Q1 2022 | -1.3% | -3.1% | +79.4% | |
| Q4 2019 | +17.0% | -2.2% | -5.9% | |
| Q4 2021 | +17.0% | -2.2% | -5.9% | |
| Q3 2021 | +1.1% | -1.9% | -61.9% | |
| Q3 2020 | +1.1% | -1.9% | -61.9% | |
| Q2 2020 | +3.4% | +1.9% | +11.2% | |
| Q2 2021 | +3.4% | +1.9% | +11.2% | |
| Q1 2021 | +11.9% | +14.8% | +35.8% | |
| Q4 2020 | -10.2% | -23.2% | -27.2% | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro